Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (3592)	6/19/1998 10:41:00 PM
From: mauser96	Read Replies (2) \| Respond to of 9523

The FDA would much rather have 1000 people suffer or die from the lack of a drug than have 10 people suffer or die from a bad reaction to the drug. The former don't know that they are being hurt, but the latter results in a lot of bad publicity. In any case, especially for a drug used to treat a human disease, there is no way to be 100% sure until it is used on enough humans. The FDA accomplishes this by delay and expensive testing, but the real reason is to let enough foreigners use the drug first. Hopefully the delay fits into this category, rather than any serious doubts about the drug. When you are dealing with a condition as severe as schizophrenia, a considerable number of possible side effects can be tolerated, as long as the drug works in a reasonable percentage of cases. The rather minimal price reaction to the news was a bit surprising , but probably indicates that analysts expect only a few months delay.